Podcasts about parkinson disease

Laura Beaton chats with Nadia Mouchaileh, senior pharmacist, and Jillian Cameron, head of movement disorders and consultant neurologist at Austin Health, about device-assisted therapies for Parkinson disease. They discuss the benefits vs traditional therapies, when to refer patients to a specialised movement disorder centre and what to look for when caring for a patient using a device. Read the full article in Australian Prescriber.

FDA say there are reports that diabetes patients are missing critical safety data from their smartphone devices; A wearable continuous apomorphine infusion device has been approved for Parkinson disease ‘off' periods; New migraine and pain treatments get the green light; And a study suggest propranolol may cut stroke risk in certain patients.  

Dr. Mitch Shulman can be heard every weekday morning at 7:50 on The Andrew Carter Morning Show.

Drs. Jeff Ratliff, Nanditha Rajamani, and Andy Horn discuss the potential for wider use of algorithmic or computational approaches to guide clinical DBS programming in the clinic and the remaining hurdles. Show reference:  https://www.nature.com/articles/s41467-024-48731-1

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Parkinson Disease⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Neurology section at ⁠⁠Medbullets.com⁠⁠ Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

Drs. Jeff Ratliff, Nanditha Rajamani, and Andy Horn discuss what this study taught us about the use of deep brain stimulation when taking into account certain white matter tracts associated with key clinical Parkinson motor symptoms. Show reference: https://www.nature.com/articles/s41467-024-48731-1 

Dr. Jeff Ratliff talks with Drs. Nanditha Rajamani and Andy Horn about the challenges faced in current deep brain stimulation practices and the potential for data-driven approaches to enhance treatment outcomes. Read the related article in Nature Communication. Disclosures can be found at Neurology.org.

Dr. Jeff Ratliff talks about the FDA approval of Crexont for the treatment of Parkinson disease.  Show reference: https://jamanetwork.com/journals/jamaneurology/fullarticle/2808496

Dr. Jeff Ratliff discusses an exciting study in the world of deep brain stimulation for Parkinson disease.  Show reference: https://www.nature.com/articles/s41591-024-03196-z

In the first installment of this two-part series, Dr. Jeff Ratliff and Dr. Daniel Weintraub discuss the risks associated with the development of dementia in patients diagnosed with Parkinson disease. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209699 

Dr. Jeff Ratliff talks with Dr. Daniel Weintraub about the long-term dementia risk in Parkinson disease using data from two large, ongoing, prospective, observational studies. Read the related article in Neurology.  Disclosures can be found at Neurology.org.

Dr. Jason Crowell and Dr. Colin Hoy discuss the concept of prodromal Parkinson disease and the ethical considerations surrounding its diagnosis.  Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209522 

Dr. Jason Crowell talks with Dr. Colin Hoy about the concept of prodromal Parkinson disease and the ethical considerations surrounding its diagnosis. Read the related article in Neurology.  Disclosures can be found at Neurology.org.

Dr. Matthew Barrett and Dr. Michael S. Okun discuss the caution and deliberation needed in understanding Parkinson disease biomarkers. Show reference: https://jamanetwork.com/journals/jamaneurology/article-abstract/2820441 

Dr. Matthew Barrett talks with Dr. Michael S. Okun about the caution and deliberation needed in understanding Parkinson disease biomarkers. Read the related viewpoint piece in JAMA Neurology. Disclosures can be found at Neurology.org.

Dr. Jason Crowell and Dr. Campbell Le Heron discuss tips and recommendations to help improve apathy in folks with Parkinson disease. Show references:  https://www.neurology.org/doi/10.1212/WNL.0000000000209301  

Dr. Jason Crowell and Dr. Campbell Le Heron discuss trying to assess for apathy in folks with Parkinson disease. Show references:  https://www.neurology.org/doi/10.1212/WNL.0000000000209301 

Seizure medication recalled due to wrong strength on carton; Gene therapy gains Fast Track status for Parkinson disease; Dendritic cell vaccine being developed for pancreatic cancer; Generic version of sickle cell disease treatment Endari is made available

Dr. Jason Crowell talks with Dr. Campbell Le Heron about the association of clinical and neurocognitive factors with apathy in patients with Parkinson disease. Read the related article in Neurology.  Disclosures can be found at Neurology.org.

Parkinson's disease affects approximately 8000 Hawaii residents and causes both movement symptoms along with other changes in mood, speech, and more. Glen Higa the President of the Hawaii Parkinsons Association along with Kevin Lockette, physical therapist and Vice President are in the studio along with speech therapist Terry Kennedy talking about novel ways to help patients with this condition delay progression and improve overall function…. And maybe learn to play the harmonica in the process!

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Sameea Husain-Wilson, DO, a movement disorder specialist at the Marcus Neuroscience Institute of Baptist Health, provided clinical perspective on the use of the Syn-One diagnostic test for patients with Parkinson disease (PD). She gave an overview of how the test is utilized in clinic, ways to interpret results, and the right personnel needed to ensure an accurate diagnosis. In addition, she provided clarity on the role of alpha-synuclein in PD, the advances in research in this area, and how the test incorporates this prominent biomarker. Furthermore, Husain-Wilson detailed some of the next steps in further optimizing the test in clinical settings, highlighting the importance of other non-movement disorder specialists who will play a major role in the diagnostic evaluation of future patients with PD. Looking for more movement disorder discussion? Check out the NeurologyLive® movement disorder clinical focus page. Episode Breakdown: 1:10 – Step by step process on how Syn-One test is used; considerations after process is done 3:15 – How the test differentiates PD from other neurodegenerative disorders 9:50 – Neurology News Minute 12:20 – Value and role in assessing alpha-synuclein in PD 14:50 – Ways to further optimize Syn-One going forward The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Eli Lilly's Donanemab for Early Symptomatic Alzheimer Disease Buntanetap Improves Motor, Nonmotor and Cognitive Symptoms of Parkinson Disease in Phase 3 Study Gene Therapy AMT-130 Slows Huntington Disease Progression in Interim Phase 1/2 Trials Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

President Joe Biden is digging in his heels resisting growing calls from Democrats to step aside and not run for re-election. A respected neurologist said Mr. Biden has all the classic signs of Parkinson Disease. Meanwhile, TruNews is reminding America that Nancy Pelosi demanded the creation of a Mental Fitness Committee to examine U.S. presidents that displayed signs of mental disorders.Rick Wiles, Doc Burkhart. Airdate 07/10/2024Listen to this FULL show exclusively on Faith & Valueshttps://members.faithandvalues.com/posts/jul-09-2024-feeble-dems-fear-biden-will-take-down-entire-democratic-ticket-in-novemberJoin the leading community for Conservative Christians! https://www.FaithandValues.comYou can partner with us by visiting https://www.TruNews.com/donate, calling 1-800-576-2116, or by mail at PO Box 399 Vero Beach, FL 32961.Get high-quality emergency preparedness food today from American Reserves!https://www.AmericanReserves.comGold & Silver Re-Imagined. Buy it. Break it. Trade it. Order your Prepper Bar now!https://trunewsbar.com/It's the Final Day! The day Jesus Christ bursts into our dimension of time, space, and matter. Now available in eBook and audio formats! Order Final Day from Amazon today!https://www.amazon.com/Final-Day-Characteristics-Second-Coming/dp/0578260816/Apple users, you can download the audio version on Apple Books! https://books.apple.com/us/audiobook/final-day-10-characteristics-of-the-second-coming/id1687129858Purchase the 4-part DVD set or start streaming Sacrificing Liberty today.https://www.sacrificingliberty.com/watchThe Fauci Elf is a hilarious gift guaranteed to make your friends laugh! Order yours today!https://tru.news/faucielf

Parkinson's disease is a neurodegenerative disorder characterized by uncontrollable movements, stiffness, and cognitive decline. Curious? Come learn more! Please rate, review, and subscribe and if you have any questions, comments, concerns, queries, or complaints, please email me at neuroscienceamateurhour@gmail.com or DM me at NeuroscienceAmateurHour on Instagram.Also if you have the means/desire to financially support this podcast - please go to https://www.buymeacoffee.com/neuroscienceI really appreciate it!!!Citations and relevant papers are below. National Institute on Aging. Parkinson's Disease: Causes, Symptoms, and Treatments. National Institute on Aging. Hogg E, Frank S, Oft J, Benway B, Rashid MH, Lahiri S. Urinary Tract Infection in Parkinson's Disease. Journal of Parkinson's Disease. 2022;12(3):743-757. ‌Yu J. Stages of Parkinson's | Parkinson's Foundation. www.parkinson.org. Published 2022. ‌Zhang ZX, Dong ZH, Román GC. Early Descriptions of Parkinson Disease in Ancient China. Archives of Neurology. 2006;63(5):782. ‌2-Minute Neuroscience: Direct Pathway of the Basal Ganglia. www.youtube.com. 2-Minute Neuroscience: Indirect Pathway of the Basal Ganglia. www.youtube.com. ‌Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgraduate Medical Journal. 2007;83(980):384-388. Zhang JF, Wang XX, Feng Y, Fekete R, Jankovic J, Wu YC. Impulse Control Disorders in Parkinson's Disease: Epidemiology, Pathogenesis and Therapeutic Strategies. Frontiers in Psychiatry. 2021;12. Hisahara S, Shimohama S. Dopamine Receptors and Parkinson's Disease. International Journal of Medicinal Chemistry. 2011;2011:1-16. Houston. Tmc.edu. Published October 20, 2020. https://nba.uth.tmc.edu/neuroscience/m/s3/chapter04.html‌Ovallath S, Sulthana B. Levodopa: History and Therapeutic Applications. Annals of Indian Academy of Neurology. 2017;20(3):185-189. ‌Levodopa | Parkinson's Foundation. www.parkinson.org. https://www.parkinson.org/living-with-parkinsons/treatment/prescription-medications/levodopa‌Kelly MJ, Baig F, Hu MTM, Okai D. Spectrum of impulse control behaviours in Parkinson's disease: pathophysiology and management. Journal of Neurology, Neurosurgery & Psychiatry. 2020;91(7):703-711. ‌Gerfen CR, Surmeier DJ. Modulation of Striatal Projection Systems by Dopamine. Annual Review of Neuroscience. 2011;34(1):441-466. ‌Sayare S. The Woman Who Could Smell Parkinson's. The New York Times. https://www.nytimes.com/2024/06/14/magazine/parkinsons-smell-disease-detection.html. Published June 14, 2024. ‌Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Progress in Neurobiology. 2000;62(1):63-88. ‌Lanciego JL, Luquin N, Obeso JA. Functional Neuroanatomy of the Basal Ganglia. Cold Spring Harbor Perspectives in Medicine. 2012;2(12):a009621-a009621. Climate ConfidentWith a new episode every Wed morning, the Climate Confident podcast is weekly podcast...Listen on: Apple Podcasts SpotifySupport the Show.

In this episode, Parm interviews Chelsea “CJ” Duppen, a winner of the DDSIG platform award at CSM Boston in 2024. CJ, a fourth year PhD student at the University of North Carolina, works with Dr. Mike Lewek in the Recovery of Gait and Neurorehabilitation (ReGaiN) lab, studying gait and gait initiation impairments in people living with Parkinson Disease, as well as motor learning. Parm and CJ discuss CJ's poster, “Gait Initiation Dynamics in Parkinson Disease: Impact of Weight Shift Amplitude and Freezing of Gait.” CJ tell us about the importance of anticipatory postural adjustments for weight shifts required in gait initiation, and how these play a role in first step length. Have you ever wondered if better weight shift improved someone with PD's first step? Listen in to learn more!   The Degenerative Diseases Special Interest Group is part of the Academy of  Neurologic Physical Therapy – www.neuroPT.org  

Dr. Jeff Ratliff discusses how arm swings can help distinguish Parkinson disease from functional Parkinsonism. Show Reference:  https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mdc3.13952 

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Igancio Mata, PhD, sat down to discuss a recently published meta-analysis on the genetic backgrounds of Parkinson disease beyond traditional European populations. Mata, an associate professor in the Genomic Medicine Institute at Cleveland Clinic, provided insight on the newly identified novel loci and how the data adds to previous genome-wide association studies. In addition, he gave thoughts on the possibility of gene therapy and some of the barriers that come with it, as well as the feasibility of incorporating genetic checkpoints into clinical trial inclusion criteria.  Looking for more movement disorder discussion? Check out the NeurologyLive® movement disorder clinical focus page. Episode Breakdown: 1:10 – Meta-analysis overview 3:20 – Significance of results, how they add to the literature 6:50 – Feasibility of incorporating genetic screening into clinical trials 8:40 – Neurology News Minute 11:15 – Realistic expectations and potential with gene therapy 15:45 – Next steps in advancing this research This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Biogen Walks Away From Aducanumab to Prioritize Lecanemab and Alzheimer Disease Pipeline Updated Guidelines Published to Improve Care in Specialized Epilepsy Centers FDA Clears IND for Gene Therapy Candidate ETX101 in Dravet Syndrome Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: March 29, 2018 What does a brain look like in a patient with a functional movement disorder? Pretty normal, it turns out. But beneath the normal anatomy is a storm of aberrant signaling. Dr. Mark Hallett, Chief of the Human Motor Control Section of the NIH, describes the underlying neurophysiology in this spectrum of disorders. Produced by James E Siegler. Music by Damiano Baldoni, Kevin MacLeod, Ondrosik, and the Philadelphia String Quartet. Voiceover by Erika Mejia. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. REFERENCES Maurer CW, LaFaver K, Ameli R, Epstein SA, Hallett M, Horovitz SG. Impaired self-agency in functional movement disorders: a resting-state fMRI study. Neurology 2016;87(6):564-70. PMID 27385746Nahab FB, Kundu P, Gallea C, et al. The neural processes underlying self-agency. Cereb Cortex 2011;21(1):48-55. PMID 20378581Vuilleumier P, Chicherio C, Assal F, Schwartz S, Slosman D, Landis T. Functional neuroanatomical correlates of hysterical sensorimotor loss. Brain 2001;124(Pt 6):1077-90. Erratum in: Brain 2016;139(Pt 5):e29. PMID 11353724 DISCLOSURES Dr. Hallett receives funding from the Intramural program of the National Institute of Neurological Disorders and Stroke. No relevant conflicts of interest are present. He serves as Chair of the Medical Advisory Board for and receives honoraria and funding for travel from the Neurotoxin Institute. He may accrue revenue on US Patent: Immunotoxin (MAB-Ricin) for the treatment of focal movement disorders, and US Patent: Coil for Magnetic Stimulation and methods for using the same (H-coil); in relation to the latter, he has received license fee payments from the NIH (from Brainsway) for licensing of this patent. Supplemental research funds have been granted by BCN Peptides, S.A., for treatment studies of blepharospasm; Medtronics, Inc., for studies of deep brain stimulation; UniQure for a clinical trial of AAV2-GDNF for Parkinson Disease; Merz for treatment studies of focal hand dystonia; and Allergan for studies of methods to inject botulinum toxins. Jim is lucky enough to have no relevant competing financial interests.  We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

Jordan welcomes a variety of guests to the program to not only discuss his recent diagnosis but to raise awareness and hope for others with the same condition. The guest this hour is Cathi Thomas, RN Assistant Clinical Professor of Neurology and Program Director of the Parkinson Disease and Movement Disorder's Center at the BU Medical Campus

Today we explore the patient experience in the context of Parkinson Disease. My guest, Dr. Indu Subramanian is a neurologist at the University of California, Los Angeles and is board certified in Integrative Medicine. Her subspecialty is the diagnosis and management of patients with Parkinson Disease. We discuss her experiences, her research and the community of healthcare professionals whose common goal is to offer holistic support for patients to thrive even in the setting of a new diagnosis.  The content shared on the Mind Body MD podcast is for informational and educational purposes only and does not constitute medical advice. The information provided must not be used as a substitute for professional medical advice, diagnosis, or treatment. As a listener, you are responsible for your own health-related decisions and must consider consulting with a healthcare professional for personalized medical advice.  Tara McCannel MD PhD is a an ocular oncologist, vitreoretinal surgeon and co-founder of Seyhart Wellness. Join me on Mind Body MD as I share with you what you need to know about holistic health and wellness. I hope you will learn, get inspired, and be motivated to empower your healing, and to live your best life.

Wendy Sorem & Calissa Palches Fox Cities Parkie Pioneers  Young Onset Parkinson Disease in Women Wisconsin (Support Group) 920-810-4367 yopdwfox@gmail.com https://wiparkinson.org/location/appleton-young-onset-womens-support-group/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/appleton-engaged/message

Today, we hear from Amanda Landsbaum on Parkinson Disease. Amanda is currenly the program director of the American Parkinson Disease Association and is passionate about providing high quality, accessible programming for people and their families living with Parkinson's Disease. Tune in to hear from Amanda and her knowledge on Parkinson's!

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: July 18, 2017 Idiopathic Parkinson disease is the second most common cause of neurodegenerative disease following Alzheimer disease. The risk of Parkinson disease increases to nearly 1 in 100 in the elderly, and although we have been pharmacologically treating this disorder since the early nineteenth century, we have no cure and no definite therapy to delay disease progression. In this episode of BrainWaves, Dr. David Coughlin illustrates how some of these therapies have evolved and which classes of medications to choose when managing a patient's symptoms--from tremor to dystonia. BrainWaves podcasts and online content are intended for medical education only and should not be used to guide medical decision-making in routine clinical practice. Any cases discussed in this episode are fictional and do not contain any patient health-identifying information. The content in this episode was vetted and approved by Andres Deik. REFERENCES Anonymous. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin Neuropharmacol 2000;23(1):34-44. PMID 10682229Elias WJ, Lipsman N, Ondo WG, et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med 2016;375(8):730-9. PMID 27557301Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351(24):2498-508. PMID 15590952Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23(6):837-44. PMID 18307261Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. 1967. Neurology 1998;50(2):318-34. PMID 9484345McIntyre CC, Savasta M, Kerkerian-Le Goff L, Vitek JL. Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both. Clin Neurophysiol 2004;115(6):1239-48. PMID 15134690Olanow CW. Levodopa: effect on cell death and the natural history of Parkinson's disease. Mov Disord 2015;30(1):37-44. PMID 25502620PD Med Collaborative Group; Gray R, Ives N, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014;384(9949):1196-205. Erratum in: Lancet 2014;384(9949):1186. PMID 24928805Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301(1):63-73. PMID 19126811 We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

A 60 year-old man who has a 10 year history of Parkinson disease presents with a chief complaint of “flaking skin that just does not go away, sometimes worse, sometimes better”, stating this problem has been present for > 6 years. Concurrent health issues include HTN, dyslipidemia and generalized anxiety disorder. The affected areas are occasionally itchy and will ache when particularly severe. He has used OTC hydrocortisone cream and skin moisturizers without seeing improvement. Physical exam reveals inflamed patches on the scalp, accompanied by greasy yellow scales. Similar lesions are noted in the nasolabial folds and behind the ears and into the ear canals. Which of the following is the most likely diagnosis?A. DandruffB. Seborrheic dermatitisC. PsoriasisD. Atopic dermatitis---YouTube: https://www.youtube.com/watch?v=VgCO_kpY208&list=PLf0PFEPBXfq592b5zCthlxSNIEM-H-EtD&index=39Visit fhea.com to learn more!

In this intriguing dialogue with Dr. Christelle Baunez, a neurobiologist at Aix-Marseille University, we discuss a mysterious and small structure, the subthalamic nucleus. Christelle is known as the STN woman in France, due to her dedication to study this structure over the years. Christelle is a pioneer in the side effects related to STN stimulation in Parkinson Disease patients. Now, she is working towards understanding how STN stimulation can help people with addiction. We cover, with an historical perspective how STN became an interesting brain stimulation target, their advantages and disadvantages of its stimulation, side effects related, its connectivity and current and future applications. In addition, we discuss some of her recent fully unpublish experiments, like STN stimulation in cocaine addicted macaques and beyond. We also cover Christelle's advocacy for animal research and its important role to push the boundaries of neuroscience. Finally, Christelle shares her passion for photography and how STN should be included in the reward circuit. This conversation was an incredible learning experience for me, and I believe it will be for you too.  Thank you so much for tuning in – for this round episode number 41 of stimulating brains!

A new topical, over the ounter treatment for Erectile Dysfunction, risk factors for Parkinson Disease, preventing Heart Attacks with a new drug and a vaccine for Multiple Sclerosis.

A new topical, over the ounter treatment for Erectile Dysfunction, risk factors for Parkinson Disease, preventing Heart Attacks with a new drug and a vaccine for Multiple Sclerosis.See omnystudio.com/listener for privacy information.

In this episode, host Parm Padgett talks with Mike Lewek and CJ Duppen from the University of North Carolina at Chapel Hill about using implicit and explicit motor learning techniques with people with Parkinson Disease. CJ and Mike do a deep dive into their research on the integration of targeted rhythmic auditory cueing to improve step length and gait speed. Additionally, they discuss their current work looking at the effects of cueing on gait initiation, step length and step speed, and weight shifting for better anticipatory postural adjustments, all aimed at positively impacting PD symptom progression and mitigating fall risk. The Degenerative Diseases Special Interest Group is part of the Academy of Neurologic Physical Therapy – www.neuroPT.org Show notes available here: https://www.neuropt.org/docs/default-source/degenerative-diseases-sig/4d-podcast-show-notes---2019/ddsig-podcast-show-notes-2023/show-notes_episode43.pdf

In today's episode, we have a conversation with a pair of directors. We'll be hearing from Iyad H. Amer, the director of "The Long Road to Hope - Ending Parkinson Disease," ," and Chris Casaceli, the director of "Our World in Our Words." Our show's initial portion will be conducted in English, followed by our inaugural international interview segment, which will be in Spanish. Over the next 6 weeks or so leading up to the festival, we will be presenting a series of shows every Friday that will feature the documentaries we are showing. We will talk with the filmmakers about their films, and the host for this series of shows will be two of the young guys who work with us here at the film office, Daniel Aniceto and Rafael Portillo, both are avid filmmakers and understand the process of making films. I think you will find theses shows interesting and informative. If you'd like to find out more about the documentary film festival please visit our website at www.Calcapdocfest.org where you will find information on all the films we are screening, view the trailers, check out the screening schedule, get information on the screening locations, and look at the various packages we have as far as getting tickets which we have purposefully kept very low and affordable. So please sit back and be inspired by these weeks interviews with our documentary film makers. I hope you enjoy the show and we hope to see you at the California Capital International Documentary Film Festival

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, James Beck, PhD, senior vice president and chief scientific officer of the Parkinson's Foundation provided perspectives on a recently published Medicare claims study that highlighted major gaps and disparities in access to Parkinson disease care. He spoke on the significance of the findings, including the lack of movement disorder specialists and issues with access to mental health professionals despite high rates of depression in this patient population. Furthermore, he spoke on the ways to make specialized care for Parkinson disease more obtainable, especially for those in rural or underserved communities. Looking for more movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page. Episode Breakdown: 1:15 – Overview of Medicare study and objectives 2:20 – Greatest clinical take-home points from the data 4:15 – Utilizing resources to cover gaps in access 5:30 – Neurology News Minute 8:05 – Reasons for lack of mental health professional support 10:55 – Challenges with understanding depression in PD 12:35 – Ensuring access to PD care in rural/underserved communities This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Sandoz's Natalizumab-sztn as First Biosimilar for Multiple Sclerosis Duchenne Agent Pamrevlumab Fails to Meet Primary End Point in Phase 3 LELANTOS-2 Trial FDA Issues Ravulizumab Complete Response Letter for NMOSD, Citing Needed Changes to REMS Program Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Dr. Sarah Camargos interviews Dr. Thiago Leal and Dr. Ignacio Mata about the need of genetic studies on underrepresented populations and the technical challenges they faced when alayzing admixture ancestries and X chromosome. Read the article

The July 2023 replay of past episodes showcases five interviews on social determinants of health in neurology. The episode begins with an interview with Dr. Heather Leeper on the links between pain and depression with unemployment due to CNS cancer. The episode continues with an interview with Dr. Wyatt Bensken on racial and ethnic difference in antiseizure medication prescription. The next interview is with Dr. Scott Mendelson on race-ethnic disparities in stroke thrombolysis. The fourth interview is with Dr. Vikas Kotagal on neighborhood socioeconomic factors in people with various movement disorders. The final episode is with Dr. Daniel Di Luca on racial and ethnic differences in quality of life among people with Parkinson's disease.   Related Podcast Links: Links Between Pain & Depression with Unemployment Due to CNS Cancer:  https://directory.libsyn.com/episode/index/id/26356875 Racial and Ethnic Differences in Antiseizure Medications Among People with Epilepsy on Medicaid: https://directory.libsyn.com/episode/index/id/25916646 Race-Ethnic Disparities in Stroke Thrombolysis: https://directory.libsyn.com/episode/index/id/23377391 Social Determinants of Health in Patients with Movement Disorders: https://directory.libsyn.com/episode/index/id/26531040 Racial and Ethnic Differences in Quality of Life in Parkinson Disease: https://directory.libsyn.com/episode/index/id/27196008 Related Article Links: Association of Employment Status With Symptom Burden and Health-Related Quality of Life in People Living With Primary CNS Tumors: https://n.neurology.org/content/100/16/e1723 Racial and Ethnic Differences in Antiseizure Medications Among People With Epilepsy on Medicaid: A Case of Potential Inequities: https://cp.neurology.org/content/13/1/e200101  Race-Ethnic Disparities in Rates of Declination of Thrombolysis for Stroke: https://n.neurology.org/content/98/16/e1596 Neighborhood Social Determinants of Health in Patients Seen in Neurology Movement Disorders Clinics: https://cp.neurology.org/content/13/2/e200142 Racial and Ethnic Differences in Health-Related Quality of Life for Individuals With Parkinson Disease Across Centers of Excellence: https://n.neurology.org/content/100/21/e2170   Visit NPUb.org/Podcast for associated article links

Dr. Daniel Garbin Di Luca discusses racial and ethnic differences in health-related quality of life for individuals with Parkinson's disease.  Show References: https://n.neurology.org/content/100/21/e2170/tab-cme  This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

Dr. Jason Crowell talks with Dr. Daniel Garbin Di Luca about racial and ethnic differences in health-related quality of life for individuals with Parkinson disease. Read the related article in Neurology. For links to articles and previous podcast episodes, please visit NPUb.org/Podcast. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

In this episode, we talk with Dr. Merrill Landers and Dr. Ryan Duncan about their presentation at APTA's CSM 2023, entitled “Mind Over Movement: Fear-Avoidance Behaviors Impacting Movement and Participation in Parkinson's Disease.” Host Chris Burke talks with Merrill and Ryan about different types of fears and fear-avoidance cycles that have been studied in individuals diagnosed with Parkinson Disease, but likely also extend to other neurologic and neurodegenerative conditions. Fear of falling, fear of pain, fear of stigma, fear of progression and fear of incontinence are all covered, as well as PTs' unique roles in identifying fears, referring for treatment, and addressing behaviors when appropriate. Listen in to this lively duo to hear how we can be more aware of these factors and modify our care to allow patients to be as active as possible. The Degenerative Diseases Special Interest Group is part of the Academy of Neurologic Physical Therapy – www.neuroPT.org

The June 2023 replay of past episodes showcases a selection of interviews regarding the biomarker discovery in Parkinson disease. This episode begins with an overview of the latest in Parkinson's research, including biomarker development with Dr. Bas Bloom. The episode continues with an interview with Dr. Lucilla Parnetti about the clinical application of α-synuclein seed amplification, leading into an interview with Prof. Andrew Siderowf about seed amplification in PD in the PPMI cohort. The June Neurology Recall concludes with an interview with Dr. Christopher Gibbons on skin α-synuclein in MSA and PD.   Related Links: Research in Movement Disorders in 2022: A New Era of Biomarker and Treatment Development: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00494-X/fulltex Podcast Link: https://directory.libsyn.com/episode/index/id/26775207 α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward: https://n.neurology.org/content/99/5/195  Podcast Link: https://directory.libsyn.com/episode/index/id/23923047 Assessment of Heterogeneity Among Participants in the Parkinson's Progression Markers Initiative Cohort Using α-Synuclein Seed Amplification: A Cross-Sectional Study: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00109-6/fulltext Podcast Link: https://directory.libsyn.com/episode/index/id/26961315  Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease: https://n.neurology.org/content/100/15/e1529 Podcast Link: https://directory.libsyn.com/episode/index/id/26499948   For links to articles and previous podcast episodes, please visit NPUb.org/Podcast.

In this episode, we talk with Dr. Alicia Flach, who was awarded the DD SIG 2023 Combined Sections Meeting (CSM) best poster award for her poster entitled “Education and Exercise Support for Individuals Newly Diagnosed with Parkinson Disease and Their Care Partners”. She and her team created educational modules and promoted self-driven exercise habits through local YMCA membership for both persons diagnosed with Parkinson's Disease and their care partners. Host Chris Burke and Alicia discuss program outcomes, including participation at the gym, overall physical activity and perceived social support. Listen in to learn more about this innovative program targeting more inclusion of care partners in physical activity and education. The Degenerative Diseases Special Interest Group is part of the Academy of Neurologic Physical Therapy – www.neuroPT.org Show notes available: https://app.box.com/s/b80eld2lxj65brgrb8e7yd95vdgrk931

Dr. Raúl Martínez-Fernández discusses his paper, "Prospective Long-term Follow-up of Focused Ultrasound Unilateral Subthalamotomy for Parkinson Disease". Show references: https://n.neurology.org/content/100/13/e1395

Dr. Jeff Ratliff talks with Dr. Raúl Martínez-Fernández about the long-term outcome of unilateral FUS-STN treatment for Parkinson disease. Read the related article in Neurology®.

Dr. Christopher Gibbons discusses his paper, "Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease". Show references: https://n.neurology.org/content/early/2023/01/19/WNL.0000000000206772 This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.